Skip to main content
ZYUS Life Sciences Corporation logo

ZYUS Life Sciences Corporation — Investor Relations & Filings

Ticker · ZYUS ISIN · CA9899601095 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2024-01-03 Regulatory Filings
Country CA Canada
Listing TSXV ZYUS

About ZYUS Life Sciences Corporation

https://www.zyus.com/

ZYUS Life Sciences Corporation is a clinical-stage life sciences company dedicated to the development and commercialization of novel, non-opioid pharmaceutical drug candidates. The company focuses on proprietary cannabinoid-based therapeutics, or phyto-therapeutics, targeting the treatment of chronic and neuropathic pain. ZYUS's vision is to redefine the standard of care in pain management by developing evidence-based alternatives to conventional treatments, including opioids and NSAIDs. The core business involves advancing these drug product candidates through clinical trials, exemplified by the ongoing Phase 2a UTOPIA-1 trial evaluating a novel non-opioid pain drug.

Recent filings

Filing Released Lang Actions
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2024-01-03 English
News release - English.pdf
Regulatory Filings
2023-12-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of a Phase 2 clinical trial for a pharmaceutical product candidate by ZYUS Life Sciences Corporation. It discusses the clinical trial design, medical leadership, and strategic decisions related to drug development. There are no financial statements, regulatory filings, or detailed financial data. The content is primarily a corporate announcement about clinical development progress, not a financial report, regulatory filing, or shareholder meeting material. It fits best as a general regulatory announcement or corporate update. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8806 characters) and content confirm it is not a brief report publication announcement or a certification letter.
2023-12-05 English
News release - English.pdf
Regulatory Filings
2023-11-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CFO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2023. The document is a certification letter and does not contain actual financial statements or substantive financial data. It explicitly states it is a certification and notes differences from non-venture issuer certifications. The document length is 3057 characters, which is relatively short and consistent with a certification letter rather than a full interim report. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report itself (IR).
2023-11-30 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended September 30, 2023. It is a certification letter rather than the actual interim report or MD&A containing substantive financial data. The document is relatively short (3093 characters) and primarily serves as an officer attestation. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as an Interim Report (IR).
2023-11-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.